Blog
RSS FeedPosted by Michael Wonder on 05 Sep 2023
NICE recommends Chiesi’s Elfabrio for adults with Fabry disease
4 September 2023 - NICE has recommended Chiesi’s Elfabrio (pegunigalsidase alfa) as a long-term option for treating Fabry disease in ...
Posted by Michael Wonder on 18 Aug 2023
NICE draft guidance recommends novel treatment for debilitating inherited skin condition
18 August 2023 - Around 670 people in England with painful and debilitating skin wounds caused by a rare inherited disorder ...
Posted by Michael Wonder on 26 Jul 2023
Afamelanotide acetate for the treatment of patients with erythropoietic protoporphyria
27 July 2023 - NICE has published final evidence-based recommendations on the use of afamelanotide acetate (Scenesse) for the treatment ...
Posted by Michael Wonder on 26 Jul 2023
Selpercatinib for untreated RET fusion positive advanced non-small-cell lung cancer
26 July 2023 - NICE has published final evidence-based recommendations on the use of selpercatinib (Retsevmo) for adults with advanced, ...
Posted by Michael Wonder on 12 Jul 2023
Lorlatinib for the treatment of adults with advanced ALK positive non-small-cell lung cancer
12 July 2023 - NICE has published final evidence-based recommendations on the use of lorlatinib (Lorviqua) for the treatment of ...
Posted by Michael Wonder on 05 Jul 2023
Rimegepant sulphate for the prevention of migraine
5 July 2023 - NICE has published final evidence-based recommendations on the use of rimegepant sulphate (Vydura) for the prevention ...
Posted by Michael Wonder on 22 Jun 2023
Upadacitinib monohydrate for the treatment of patients with previously treated moderately to severely active Crohn’s disease
21 June 2023 - NICE has published final evidence-based recommendations on the use of upadacitinib monohydrate (Rinvoq) for the treatment ...
Posted by Michael Wonder on 21 Jun 2023
Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer
21 June 2023 - NICE has published final evidence-based recommendations on the use of pembrolizumab (Keytruda) in combination with lenvatinib ...
Posted by Michael Wonder on 21 Jun 2023
Darolutamide in combination with androgen deprivation therapy and docetaxel for the treatment of patients with hormone-sensitive metastatic prostate cancer
21 June 2023 - NICE has published final evidence-based recommendations on the use of darolutamide (Nubeqa) in combination with androgen ...
Posted by Michael Wonder on 21 Jun 2023
Dapagliflozin propanediol monohydrate for the treatment of adults with chronic heart failure with preserved or mildly reduced ejection fraction
21 June 2023 - NICE has published final evidence-based recommendations on the use of dapagliflozin propanediol monohydrate for the treatment ...
Posted by Michael Wonder on 20 Jun 2023
Cemiplimab for the treatment of patients with recurrent or metastatic cervical cancer
20 June 2023 - NICE is unable to make a recommendation on the use of cemiplimab (Libtayo) for the treatment of ...
Posted by Michael Wonder on 14 Jun 2023
Tixagevimab and cilgavimab for the prevention of COVID-19 disease
14 June 2023 - NICE has published final evidence-based recommendations on the use of tixagevimab and cilgavimab (Evusheld) for the ...
Posted by Michael Wonder on 14 Jun 2023
Dabrafenib mesylate and trametinib dimethyl sulphoxide for the treatment of patients with advanced BRAF V600 mutation positive non-small-cell lung cancer
14 June 2023 - NICE has published final evidence-based recommendations on the use of dabrafenib mesylate (Tafinlar) and trametinib dimethyl ...
Posted by Michael Wonder on 07 Jun 2023
Bulevirtide acetate for the treatment of adults with chronic hepatitis D (final guidance)
7 June 2023 - NICE has published final evidence based recommendations on the use of bulevirtide (Hepcludex) for the treatment ...
Posted by Michael Wonder on 07 Jun 2023
Axicabtagene ciloleucel for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy
7 June 2023 - NICE has published final evidence-based recommendations on the use of axicabtagene ciloleucel (Yescarta) for the treatment ...